Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma

The goal of this clinical trial is to evaluate the addition of ivonescimab to standard chemotherapy in patients with advanced or metastatic gastric and gastroesophageal adenocarcinoma. The main question it aims to answer is : Does the addition of ivonescimab increase the response to treatment ? Participants will visit the clinic every 2 weeks for checkups, treatment administration and tests for collection of adverse events.

Trial Details

NCT ID
NCT06846346
Phase
PHASE2
Sponsor
UNICANCER
Status
RECRUITING
Cancer Type
Adenocarcinoma Esophageal Cancer
Interventions
  • Ivonescimab
  • FOLFOX regimen
  • Irinotecan
  • Paclitaxel
Locations (sample)
  • Lyon, France|45.74906,4.84789
  • Marseille, France|43.29695,5.38107
  • Reims, France|49.26526,4.02853
  • Saint-Herblain, France|47.21154,-1.651

Key Eligibility Criteria

  • Signed a written informed consent form prior to any trial specific procedures. Note: If the patient is physically unable to provide their written c…
  • Histologically or cytologically proven gastric cancer (GC) or esophagogastric junction cancer adenocarcinoma (EGJC)
  • Metastatic or locally advanced non resectable (stage IV) disease.
  • Presence of at least one measurable lesion as assessed by the investigator according to RECIST v1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Esophageal Cancer Trials on Trialify →